15th Oct 2012 09:11
15 October 2012 Source BioScience plc (the `Company') Additional Listing on Exercise of Share Options
Source BioScience plc announces that it has issued 1,018,034 new ordinary shares of 2 pence each in the Company (the `New Ordinary Shares'), representing 0.50% of its enlarged issued share capital, following the election by certain option holders to exercise options under the Source BioScience Group plc Share Option Schemes.
An application has been made for the New Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. It is expected that admission of the New Ordinary Shares will occur on or around 18 October 2012.
Following the issue and allotment, the Company's issued share capital will comprise 204,783,266 ordinary shares of 2 pence each, which figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FSA's Disclosure and Transparency Rules. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares.
--- ENDS ---
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO and Company SecretaryTel: +44 (0)115 973 9010Email: [email protected]
For investor and media enquiries:
N+1 Singer (Financial Advisor, Sponsor and Broker)
Aubrey Powell/Luke BoyceTel: +44 (0)20 3201 3710www.nplus1singer.com
College Hill (PR Agency to Source BioScience)
Melanie Toyne-Sewell/Stefanie BacherTel: +44 (0)20 7457 2020Email: [email protected]
About Source BioScience:
Source BioScience plc is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Company is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com
XLONRelated Shares:
SBS.L